Cara Therapeutics Inc.

11.94-0.6700-5.31%Vol 669.13K1Y Perf -31.93%
Jul 23rd, 2021 16:00 DELAYED
BID11.92 ASK11.94
Open12.57 Previous Close12.61
Pre-Market- After-Market11.94
 - -  - -%
Target Price
27.29 
Analyst Rating
Strong Buy 1.29
Potential %
128.56 
Finscreener Ranking
★★★★★     64.46
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     61.60
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     84.15
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap597.62M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
0.78 
Earnings Date
9th Aug 2021

Today's Price Range

11.8912.57

52W Range

11.8029.65

5 Year PE Ratio Range

-6.10-7.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.08%
1 Month
-17.71%
3 Months
-54.67%
6 Months
-37.65%
1 Year
-31.93%
3 Years
-35.98%
5 Years
96.06%
10 Years
-

TickerPriceChg.Chg.%
CARA11.94-0.6700-5.31
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
10.60
11.40
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
9.20
9.30
-14 927.50
35.06
RevenueValueIndustryS&P 500US Markets
123.29M
2.46
196.63
222.18
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.62-0.4724.19
Q04 2020-0.531.59400.00
Q03 2020-0.68-0.3548.53
Q02 2020-0.68-0.5420.59
Q01 2020-0.63-0.621.59
Q04 2019-0.62-0.611.61
Q03 2019-0.59-0.74-25.42
Q02 2019-0.61-0.584.92
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.5415.63Positive
9/2021 QR-0.4112.77Positive
12/2021 FY-1.7516.27Positive
12/2022 FY-1.32-55.29Negative
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.54
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume669.13K
Shares Outstanding50.05M
Trades Count8.47K
Dollar Volume7.98M
Avg. Volume863.28K
Avg. Weekly Volume412.13K
Avg. Monthly Volume443.62K
Avg. Quarterly Volume859.02K

Cara Therapeutics Inc. (NASDAQ: CARA) stock closed at 11.94 per share at the end of the most recent trading day (a -5.31% change compared to the prior day closing price) with a volume of 669.34K shares and market capitalization of 597.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Cara Therapeutics Inc. CEO is Derek T. Chalmers.

The one-year performance of Cara Therapeutics Inc. stock is -31.93%, while year-to-date (YTD) performance is -21.08%. CARA stock has a five-year performance of 96.06%. Its 52-week range is between 11.8 and 29.65, which gives CARA stock a 52-week price range ratio of 0.78%

Cara Therapeutics Inc. currently has a PE ratio of 39.40, a price-to-book (PB) ratio of 2.82, a price-to-sale (PS) ratio of 5.27, a price to cashflow ratio of 69.60, a PEG ratio of 2.32, a ROA of 6.12%, a ROC of 7.02% and a ROE of 7.00%. The company’s profit margin is 35.06%, its EBITDA margin is 9.30%, and its revenue ttm is $123.29 Million , which makes it $2.46 revenue per share.

Of the last four earnings reports from Cara Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Cara Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Cara Therapeutics Inc. is Strong Buy (1.29), with a target price of $27.29, which is +128.56% compared to the current price. The earnings rating for Cara Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cara Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.56, ATR14 : 0.52, CCI20 : -151.80, Chaikin Money Flow : 0.07, MACD : -0.50, Money Flow Index : 16.55, ROC : -13.79, RSI : 23.77, STOCH (14,3) : 1.92, STOCH RSI : 0.00, UO : 44.83, Williams %R : -98.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cara Therapeutics Inc. in the last 12-months were: Christopher Posner (Sold 6 304 shares of value $93 320 ), Derek T. Chalmers (Sold 58 410 shares of value $967 032 ), Frederique Menzaghi (Sold 11 173 shares of value $200 108 ), Jeffrey L. Ives (Sold 7 520 shares of value $111 631 ), Joana Goncalves (Sold 25 763 shares of value $482 812 ), Martin A. Vogelbaum (Sold 20 640 shares of value $305 832 ), Scott M. Terrillion (Sold 9 040 shares of value $162 729 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (75.00 %)
6 (75.00 %)
Moderate Buy
0 (0.00 %)
1 (12.50 %)
1 (12.50 %)
Hold
1 (14.29 %)
1 (12.50 %)
1 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.38
Strong Buy
1.38

Cara Therapeutics Inc.

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

CEO: Derek T. Chalmers

Telephone: +1 203 406-3700

Address: 107 Elm Street, 9th Floor, Stamford 06902, CT, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

News

Stocktwits